Protect intellectual property and incentives for discovering and commercializing new therapies and technology.

Protect IP and ensure incentives for discovery & commercialization of new therapies & technology.

Auchincloss committed to protecting IP and incentives for medical and technology discovery and commercialization.

An Update from Your Congressman
primary · official_post · model gpt-5.5

unverified · Source version 91397 · locator unknown

"Mr. LANGWORTHY (for himself, Mr. AUCHINCLOSS, Mr. JOYCE of Pennsylvania, Ms. SÁNCHEZ, Mr. PETERS, Mr. YAKYM, Mr. MORAN, Mr. MULLIN, and Mr. PANETTA) introduced the following bill; which was referred to the Committee on Energy and Commerce"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Within the 30-day lookback window, Auchincloss was an original House cosponsor of a bill addressing when biosimilar biologics are subject to Medicare price negotiations. The bill was introduced and referred, not enacted, so it is evidence of effort rather than completed delivery.

unresolved later_term A for effort

BILLS-119hr10628ih.pdf
secondary · model gpt-5.5 · confidence 83%

unverified · Source version 91399 · locator unknown

"Auchincloss is leading an effort to promote the Cures in Care Initiative, a bi-partisan legislation that would create a network of point-of-care clinical trial platforms to address rare diseases and reduce the time required to launch Phase I trials."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): During the lookback window, reporting from UMass Chan described Auchincloss continuing to promote clinical-trials legislation aimed at accelerating therapy development. It shows ongoing effort on incentives and commercialization pathways for therapies, but no enactment.

unresolved later_term A for effort

U.S. Rep. Jake Auchincloss visits UMass Chan to discuss research funding cuts, point-of-care clinical trials
secondary · model gpt-5.5 · confidence 78%

unverified · Source version 91401 · locator unknown

"We can have both, with strong intellectual property laws, with insurance design that lowers, or limits, copays, and with negotiations that prioritize value as opposed to rebates."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): In an official 2026 hearing, Auchincloss tied drug-pricing legislation to strong IP protections and innovation/manufacturing incentives. This is concrete advocacy, not a final policy outcome.

unresolved later_term A for effort

HHRG-119-IF14-Transcript-20260211.pdf
secondary · model gpt-5.5 · confidence 86%

unverified · Source version 91403 · locator unknown

"The draft framework will hamstring U.S. innovation to the advantage of our competitors and adversaries, and thus, we urge you to reconsider the NIST proposal. Sincerely, Christopher A. Coons United States Senator Thom Tillis United States Senator Darrell Issa Member of Congress Jake Auchincloss Member of Congress"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Auchincloss signed a bipartisan letter opposing proposed Bayh-Dole march-in guidance that the signers argued would weaken patent-backed commercialization incentives. This is evidence of concrete effort to protect IP incentives, not enacted delivery.

unresolved later_term A for effort

DB9A4396-776E-44A1-B123-402DD121F6A2
secondary · model gpt-5.5 · confidence 90%

unverified · Source version 91405 · locator unknown

"As of December 2025, NIST had not finalized the guidance."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): GAO reported that the Bayh-Dole march-in guidance Auchincloss opposed had not been finalized as of December 2025. This suggests the perceived threat to IP incentives remained unresolved rather than enacted or permanently defeated.

unresolved later_term

Intellectual Property: Information on Draft Guidance to Assert Government Rights Based on Price | U.S. GAO
secondary · model gpt-5.5 · confidence 82%

unverified · Source version 91407 · locator unknown

"to further incentivize industry participation in public-private partnerships for the purposes of accelerating technology research and commercialization"

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The enacted CHIPS and Science Act included provisions to incentivize technology research and commercialization and protect federally funded IP. Together with Auchincloss's recorded Yea vote on final House passage, this supports partial delivery for the technology side of the commitment, though not the full therapy/IP promise.

partial same_term

PLAW-117publ167.pdf
secondary · model gpt-5.5 · confidence 80%